ECSP23003649A - Agonistas del receptor npy2 solubles antecedentes de la invención - Google Patents

Agonistas del receptor npy2 solubles antecedentes de la invención

Info

Publication number
ECSP23003649A
ECSP23003649A ECSENADI20233649A ECDI202303649A ECSP23003649A EC SP23003649 A ECSP23003649 A EC SP23003649A EC SENADI20233649 A ECSENADI20233649 A EC SENADI20233649A EC DI202303649 A ECDI202303649 A EC DI202303649A EC SP23003649 A ECSP23003649 A EC SP23003649A
Authority
EC
Ecuador
Prior art keywords
soluble
receptor agonists
npy2 receptor
agonists background
analogues
Prior art date
Application number
ECSENADI20233649A
Other languages
English (en)
Inventor
Albert Brennauer
Charlotte Madsen
Peter Haebel
Stefan Peters
Soren Pedersen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP23003649A publication Critical patent/ECSP23003649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.
ECSENADI20233649A 2020-08-07 2023-01-17 Agonistas del receptor npy2 solubles antecedentes de la invención ECSP23003649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20189966 2020-08-07
PCT/EP2021/071873 WO2022029231A1 (en) 2020-08-07 2021-08-05 Soluble npy2 receptor agonists

Publications (1)

Publication Number Publication Date
ECSP23003649A true ECSP23003649A (es) 2023-03-31

Family

ID=71995807

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20233649A ECSP23003649A (es) 2020-08-07 2023-01-17 Agonistas del receptor npy2 solubles antecedentes de la invención

Country Status (19)

Country Link
US (1) US20220041678A1 (es)
EP (1) EP4192853A1 (es)
JP (1) JP2023537036A (es)
KR (1) KR20230045088A (es)
CN (1) CN116171282A (es)
AR (1) AR123174A1 (es)
AU (1) AU2021322137A1 (es)
BR (1) BR112022025623A2 (es)
CA (1) CA3185637A1 (es)
CL (1) CL2023000357A1 (es)
CO (1) CO2023000637A2 (es)
CR (1) CR20230074A (es)
DO (1) DOP2023000010A (es)
EC (1) ECSP23003649A (es)
IL (1) IL300239A (es)
MX (1) MX2023001532A (es)
PE (1) PE20231566A1 (es)
TW (1) TW202222335A (es)
WO (1) WO2022029231A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022210988B9 (en) 2021-01-20 2024-02-22 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525495A (ja) 2004-02-11 2007-09-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
BRPI0518559A2 (pt) 2004-12-13 2008-11-25 Amylin Pharmaceuticals Inc motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
KR101593406B1 (ko) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 글루카곤 유사체
PL2454282T3 (pl) 2009-07-13 2015-08-31 Zealand Pharma As Acylowane analogi glukagonu
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
PL2718316T3 (pl) 2011-06-10 2020-06-29 Novo Nordisk A/S Polipeptydy
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
KR102184241B1 (ko) 2012-05-03 2020-12-01 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
ES2732291T3 (es) 2013-05-02 2019-11-21 Glaxosmithkline Ip Dev Ltd Péptidos terapéuticos
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EP3057984B1 (en) 2013-10-17 2018-07-11 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
MX2016006049A (es) 2013-11-14 2016-08-12 Keybioscience Ag Mimeticos de calcitonina para tratar enfermedades y trastornos.
RS59026B1 (sr) 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
JP6769984B2 (ja) 2015-03-18 2020-10-14 ジーランド ファーマ アクティーゼルスカブ アミリン類似体
MX2017012864A (es) 2015-04-16 2018-06-12 Zealand Pharma As Analogo acilado del glucagon.
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
HRP20220995T1 (hr) 2015-12-31 2022-11-11 Hanmi Pharm. Co., Ltd. Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JOP20190097A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv الجلوبولينات المناعية واستخداماتها
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
JP2023500895A (ja) * 2019-11-11 2023-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎｐｙ２受容体アゴニスト

Also Published As

Publication number Publication date
JP2023537036A (ja) 2023-08-30
AU2021322137A1 (en) 2023-01-19
WO2022029231A1 (en) 2022-02-10
CN116171282A (zh) 2023-05-26
MX2023001532A (es) 2023-03-08
US20220041678A1 (en) 2022-02-10
IL300239A (en) 2023-03-01
EP4192853A1 (en) 2023-06-14
CA3185637A1 (en) 2022-02-10
AR123174A1 (es) 2022-11-02
CO2023000637A2 (es) 2023-01-26
BR112022025623A2 (pt) 2023-03-07
TW202222335A (zh) 2022-06-16
KR20230045088A (ko) 2023-04-04
DOP2023000010A (es) 2023-02-15
CL2023000357A1 (es) 2023-09-29
CR20230074A (es) 2023-04-19
PE20231566A1 (es) 2023-10-04

Similar Documents

Publication Publication Date Title
ECSP23003649A (es) Agonistas del receptor npy2 solubles antecedentes de la invención
CL2022001227A1 (es) Agonistas del receptor npy2
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
EP2496245A4 (en) ANALOG OF PITUTIC ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHOD OF USE THEREOF
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
NZ743487A (en) Controlled-release cnp agonists with increased nep stability
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
UY38707A (es) Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
NI202000071A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
MX2018012716A (es) Peptidos bioactivos pegilados y usos de los mismos.
BR112022006297A2 (pt) Agonistas de receptor de npy2
MX2016004660A (es) Composiciones de peptido novedosas.
EA202192475A1 (ru) Способ получения стабильных пептидных составов
BR112022003751A2 (pt) Análogos de hemoglobina reticulada com tiosuccinila e métodos de uso e preparação dos mesmos
AR116636A1 (es) Radiofármacos dirigidos a grpr y usos de los mismos
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
UY38706A (es) Antagonistas cíclicos del receptor b2 de bradiquinina